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Preface
This issue ofEnvirmnmentalHealthPerspectives is the
first of two volumes comprising papers presented at the
Conference on"BiomonitoringandSusceptibilityMarkers
in Human Cancer: Applications in Molecular Epidemiol-
ogy and Risk Assessment," which was held October 26
through November 1, 1991, in Kailua-Kona, Hawaii. This
conference was organizedbythe InternationalAgencyfor
Research on Cancer (IARC, Lyon, France) and by the
National Center for Toxicological Research/FDA (NCTR,
Jefferson, Arkansas, USA), and was additionally spon-
sored by the U.S. Environmental Protection Agency, the
Commission of the European Communities, the Health
Effects Institute, and the U.S. National Cancer Institute.
This first volume focuses on biomarkers of suscep-
tibility andincludespapers ona)therelationship ofmolec-
ular,chromosomal, andcellularsusceptibilitymarkersand
the multistage carcinogenesis process in humans; and b)
the role of genetic polymorphism of xenobiotic-metabol-
izingenzymes in cancer susceptibility. The secondvolume
describes a) recent progress in biomonitoring techniques
andmolecular dosimetryapproaches andtheirapplication
to various populations exposed to carcinogens; and b)
issues and implications for using biomarkers in cancer
epidemiology and risk assessment.
Interest is increasing in organizing multidisciplinary
meetings that bring together experimental oncologists,
cancer epidemiologists, geneticists, and clinicians to
explore the potential of integrated laboratory and field
studies.Although oneofthefirstmeetings ofthiskindwas
in 1972,1 progress was slow in the following decade, as
available knowledge was too limited to allow any recom-
mendationsusefulforcancercontrolandprevention. How-
ever, the concept of combined laboratory and epidemio-
logical studies ofhuman cancer was then recognized and
gainedsupport, asevidencedinsubsequent25 conferences
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conferences. This new approach has since been named
metabolic, biochemical, or molecular epidemiology.
This latest meeting discussed recently developed
markers for use in molecular epidemiological studies for
identifying subpopulations and (hopefully) individuals at
higherriskforcancer, eitherbecausetheyaremorehighly
exposed to carcinogens or because inherited or acquired
host factors render them more susceptible. For these
individuals, onceidentified, steps canbetakentominimize
exposure. A note of caution, however, is needed when
discussinggeneticvariationsandsusceptibilitytoenviron-
mental agents. It is essential that any scientific results
that showanelevated, relative, orattributable riskassoci-
ated with any specific genetic trait in relation to specific
exposure and to disease outcome should have the most
rigorous possible methodological and theoretical basis.
Otherwise, unethical or undesirable use ofsuch informa-
tion will preclude any beneficial impact.
We are pleased that a number of epidemiologists
attended this meeting in contrast to similar conferences
wherethisdisciplinewasfrequentlyunderrepresented. In
viewofa) the pace ofdevelopment oftools frommolecular
dosimetry, molecularbiology, andgenetics, asdescribed at
this meeting, and b) the fact that many studies published
under the label of molecular epidemiology have serious
limitations of epidemiological/statistical design (and
should at best be called laboratory investigations on
human subjects), the field needs epidemiologists inter-
ested in developingnewstrategiesforthe efficientdeploy-
ment ofthese biomarkers.
We hope that the major advances presented at this
meeting, along with the excellent presentations and
enthusiasm of the participants, will accelerate ongoing
research in molecular and biochemical epidemiology. In
turn, this should significantly improve the process of
cancer risk assessment and prevention and protect the
public health.
Finally,wearegratefulto M.Anderson, X. Bosch, C. C.
Harris, R. Hayes, S. S. Hecht, P. Kleihues, J. Lewtas, A.
Likhachev, G. Lucier, F. P. Perera, R. J. Scheuplein, D.
Shuker, A. Sivak, S. R. Tannenbaum, P. Vineis, C. R Wild,
and H. Yamasaki, who spent considerable time in helping
to establish the objectives ofthis symposium and assem-
bling the program.
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